Compass Pathways Plc (CMPS)

Currency in USD
8.270
-0.740(-8.21%)
Closed·
8.360+0.090(+1.09%)
·
CMPS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.1808.920
52 wk Range
4.88015.870
Key Statistics
Prev. Close
8.27
Open
8.75
Day's Range
8.18-8.92
52 wk Range
4.88-15.87
Volume
3.29M
Average Volume (3m)
3.01M
1-Year Change
55.1595%
Book Value / Share
1.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CMPS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
23.313
Upside
+181.89%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Compass Pathways Plc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

15 Buy
1 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 23.313
(+181.89% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy18.00+117.65%-MaintainNov 09, 2026
RBC Capital
Buy21.00+153.93%-MaintainNov 04, 2026
Wells Fargo
Hold10.00+20.92%13.00MaintainNov 04, 2026
Stifel
Buy21.00+153.93%-MaintainNov 04, 2026
Oppenheimer
Buy20.00+141.84%-MaintainNov 03, 2026

Compass Pathways Plc SWOT Analysis


Psychedelic Pionee
Compass Pathways leads the charge in developing psilocybin-based therapy COMP360 for treatment-resistant depression, navigating clinical trials and regulatory hurdles
Market Potential
Analysts project peak revenues of $2.3 billion for COMP360, with a potential market exceeding $1 billion in treatment-resistant depression alone
Regulatory Landscape
Explore how Compass Pathways' methodical approach aligns with FDA guidance, potentially expediting approval in an evolving regulatory environment for psychedelic therapies
Financial Outlook
With analyst price targets ranging from $12 to $60, Compass Pathways faces challenges but maintains a strong liquidity position as it advances towards commercialization
Read full SWOT analysis

Compass Pathways Plc Earnings Call Summary for Q3/2026

  • COMPASS reported Q3 2026 loss of $0.31/share, beating estimates of $0.36/share; shares surged 10.58% to $9.30 in premarket trading.
  • Company holds $444M cash, sufficient to fund operations through planned 2027 COMP360 launch and into 2028 without immediate financing needs.
  • Rolling NDA submission for psilocybin treatment COMP360 to complete within two weeks; FDA priority voucher may enable 1-2 month review timeline.
  • Management targets H1 2027 launch for treatment-resistant depression therapy; 90% of interventional psychiatrists indicated willingness to prescribe.
  • Commercial infrastructure buildout underway with REMS preparation, specialty pharmacy reimbursement strategy, and CPT code transition expected in 12-18 months.
Last Updated: 11/03/2026, 10:00 PM
Read Full Transcript

Earnings

Latest Release
Nov 03, 2026
EPS / Forecast
-0.31 / -0.36
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CMPS Income Statement

Compare CMPS to Peers and Sector

Metrics to compare
CMPS
Peers
Sector
Relationship
P/E Ratio
−4.4x−1.6x−0.2x
PEG Ratio
−0.24−0.030.00
Price/Book
8.2x2.2x2.6x
Price / LTM Sales
-3.5x2.7x
Upside (Analyst Target)
181.9%197.8%66.0%
Fair Value Upside
Unlock26.2%10.8%Unlock

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.49M8.11%103.53M
Other Institutional Investors
95.69M67.53%862.19M
Public Companies & Retail Investors
34.53M24.36%311.09M
Total
141.71M100.00%1.28B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Deep Track Capital, LP8.58%12,161,496109,575
RTW Investments, LP7.55%10,700,97496,416

People Also Watch

49.88
CRWV
-6.12%
45.160
AAOI
-9.48%
100.99
CBRS
-7.11%
107.13
NBIS
-7.55%

FAQ

What Is the Compass Pathways (CMPS) Stock Price Today?

The Compass Pathways stock price today is 8.270 USD.

What Stock Exchange Does Compass Pathways Trade On?

Compass Pathways is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Compass Pathways?

The stock symbol for Compass Pathways is "CMPS."

What Is the Compass Pathways Market Cap?

As of today, Compass Pathways market cap is 1.170B USD.

What Is Compass Pathways's Earnings Per Share (TTM)?

The Compass Pathways EPS (TTM) is -2.22.

When Is the Next Compass Pathways Earnings Date?

Compass Pathways will release its next earnings report on Mar 04, 2027.

From a Technical Analysis Perspective, Is CMPS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Compass Pathways Stock Split?

Compass Pathways has split 0 times.

How Many Employees Does Compass Pathways Have?

Compass Pathways has 156 employees.

What is the current trading status of Compass Pathways (CMPS)?

As of Nov 17, 2026, Compass Pathways (CMPS) is trading at a price of 8.270 USD, with a previous close of 8.270 USD. The stock has fluctuated within a day range of 8.180 USD to 8.920 USD, while its 52-week range spans from 4.880 USD to 15.870 USD.

What Is Compass Pathways (CMPS) Price Target According to Analysts?

The average 12-month price target for Compass Pathways is 23.313 USD, with a high estimate of 65 USD and a low estimate of 10 USD. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +181.89% Upside potential.

What Is the CMPS Premarket Price?

CMPS's last pre-market stock price is 8.900 USD. The pre-market share volume is 32,620.000, and the stock has decreased by -0.110, or -1.220%.

What Is the CMPS After Hours Price?

CMPS's last after hours stock price is 8.360 USD, the stock has decreased by 0.090, or 1.090%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.